人民财讯12月23日电，新诺威（300765）12月23日公告，控股子公司石药集团巨石生物制药有限公司近 日收到国家药监局核准签发的关于达雷妥尤单抗注射液的《药物临床试验批准通知书》，将于近期开展 临床试验。该药品适用于治疗多发性骨髓瘤成年患者。 ...

石药创新制药股份有限公司 证券代码：300765 证券简称：新诺威 公告编号：2025-101 关于控股子公司达雷妥尤单抗注射液 三、药物的其他相关情况 达雷妥尤单抗注射液是一种靶向 ADP-核糖基环化酶（CD38）的重组全人源 IgG1 单克隆抗体，为原研药兆珂®的生物类似药，按照治疗用生物制品 3.3 类申 报，适用于治疗多发性骨髓瘤成年患者。该产品研发遵循生物类似药相关研究指 1 剂 型：注射剂 注册分类：治疗用生物制品 3.3 类 申请事项：临床试验 受 理 号：CXSL2500876 申请人：石药集团巨石生物制药有限公司 获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概述 石药创新制药股份有限公司（以下简称"公司"）的控股子公司石药集团巨石 生物制药有限公司（以下简称"巨石生物"）于近日收到国家药品监督管理局核 准签发的关于达雷妥尤单抗注射液的《药物临床试验批准通知书》，将于近期开 展临床试验。现将相关情况公告如下： 二、药物的基本信息 药物名称：达雷妥尤单抗注射液 审批结论：根据《中华人民共和国药品管理法》及 ...

证券日报网讯 12月22日，新诺威发布公告称，公司第六届董事会第二十九次会议审议通过《关于与关 联方共同投资设立合资公司暨关联交易的议案》。 （文章来源：证券日报） ...

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

Core Viewpoint - The announcement reveals that XinNuoWei plans to establish a joint venture with Zhongqi Pharmaceutical, focusing on the development and commercialization of innovative metabolic drugs, particularly targeting GLP-1 related products [1] Group 1: Joint Venture Details - XinNuoWei will invest 157.5 million yuan, holding a 35% stake in the joint venture, while Zhongqi Pharmaceutical will contribute 292.5 million yuan for a 65% stake [1] - The total investment for the joint venture is set at 450 million yuan [1] Group 2: Business Focus - The joint venture will primarily focus on the research, industrialization, and commercialization of innovative metabolic drugs, targeting areas such as overweight/obesity and type 2 diabetes [1] - The company plans to develop new drug formulations and expand indications continuously [1] Group 3: Product Pipeline - The joint venture will take over all GLP-1 related product pipelines from Shijiazhuang Pharmaceutical Group, including those in preclinical research, clinical stages, and those submitted for market approval [1] - The company aims to enhance its product matrix through various methods, including independent development, rights acquisition, and pipeline introduction [1]

Core Viewpoint - The company plans to establish a joint venture with Zhongqi Pharmaceutical Technology Co., Ltd. with a total investment of 450 million RMB, focusing on the development and commercialization of innovative metabolic drugs targeting GLP-1 [1] Group 1: Joint Venture Details - The company will contribute 157 million RMB, representing 35% of the registered capital [1] - Zhongqi Pharmaceutical will invest 292 million RMB, holding 65% of the registered capital [1] - The joint venture will primarily focus on the research, industrialization, and commercialization of innovative metabolic drugs [1] Group 2: Transaction Classification - This transaction is classified as a related party transaction and does not constitute a major asset reorganization [1]

Core Viewpoint - The establishment of a joint venture between XinNuoWei and Zhongqi Pharmaceutical aims to enhance the company's position in the innovative biopharmaceutical sector, particularly focusing on GLP-1 target products, driven by increasing health awareness and medical spending in China [1][2] Group 1 - The joint venture will be funded with a total investment of 45 million RMB, with XinNuoWei contributing 15.75 million RMB (35% ownership) and Zhongqi Pharmaceutical contributing 29.25 million RMB (65% ownership) [1] - The joint venture will focus on the research, industrialization, and commercialization of innovative metabolic drugs, particularly targeting obesity and type 2 diabetes [1] - The joint venture will take over all GLP-1 related product pipelines from Shiyao Group, including preclinical, clinical, and market application stages, and will explore various methods to expand its product pipeline [2]

Group 1 - The core point of the article is that XinNuoWei (300765) announced plans to establish a joint venture with Zhongqi Pharmaceutical, contributing a total of 450 million yuan, with XinNuoWei investing 158 million yuan for a 35% stake in the new company [1] - The joint venture will focus on the research, industrialization, and commercialization of innovative metabolic drugs, particularly targeting GLP-1 related products [1] - The new company will take over the entire pipeline of GLP-1 related products from Shiyao Group Co., Ltd., which includes treatments for overweight/obesity and type 2 diabetes, and will continue to develop new formulations and expand indications [1]

每经头条（nbdtoutiao）——新能源重卡爆单了，11月销量同比增长178%！两班倒都供不应求，客户直 接进厂催单，这情景十年难遇 （记者 曾健辉） 每经AI快讯，新诺威（SZ 300765，收盘价：35.62元）12月22日晚间发布公告称，石药创新制药股份有 限公司董事会于本日（2025年12月22日）收到公司董事CAI LEI（蔡磊）先生的书面辞职报告。CAI LEI先生申请辞任公司董事职务，辞任后不再担任公司任何职务。 2024年1至12月份，新诺威的营业收入构成为：功能食品及原料行业占比92.91%，生物制药行业占比 4.43%，其他业务占比2.66%。 截至发稿，新诺威市值为500亿元。 ...

新诺威12月22日公告，公司董事会当天收到公司董事 CAI LEI（蔡磊）的书面辞职报告，蔡磊因工作变 动原因申请辞任公司董事职务，辞任后不再担任公司任何职务。蔡磊的辞职报告自送达董事会时生效。 ...